Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:57:26.607Z.
Calculation as of: 2026-10-06T15:57:26.607Z.
Quote observation: 2026-10-06T15:55:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 127c42f84a692115bc317292f5e8c44ad9cea602a51c3ca4b81ff92f7edcc32f
PE RATIO
N/A
Nutriband Inc.
Market Cap
$81.45M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Nutriband Inc. (NTRB) | $81.45M | N/A |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | N/A |
| LENSAR Inc (LNSR)vs › | $82.53M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.73M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $83.48M | N/A |
| Hyperfine, Inc. (HYPR)vs › | $76.19M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $84.78M | N/A |
Trailing P/E
N/A
Forward P/E
4.3
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$6.70
Forward EPS (Est.)
$1.57
Forward P/E
4.27
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
